Latest News
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
16 September 2024 - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage company developing novel therapies for treatment of the most aggressive cancers, announced on Monday that it showcased updated results from the NOX-A12 GLORIA Phase ...
Vico Therapeutics' VO659 Phase 1/2a clinical trial reveals new positive interim data in Huntington's disease
16 September 2024 - Netherlands-based clinical-stage genetic medicines company Vico Therapeutics BV announced on Friday that it had revealed new positive interim data in Huntington's disease (HD) from the ongoing Phase 1/2a clinical trial of VO6...
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval
16 September 2024 - California-based biopharmaceutical company Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on Friday that Roche (SWX:ROG), a Switzerland-based healthcare company, has received approval for OCREVUS ZUNOVO (ocrelizumab and hyalu...
Zydus Lifesciences signs licensing and supply agreement with Viwit Pharmaceuticals
16 September 2024 - India-based pharmaceutical company focused on manufacturing generic drugs Zydus Lifesciences Ltd. announced on Friday that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has signed an exclusive licensing and supply ag...
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
16 September 2024 - South Korea-based clinical-stage biopharmaceutical company Kine Sciences announced on Friday that the first patient has been dosed in its Phase 1b/2a clinical study of KINE-101 for Chronic Inflammatory Demyelinating Polyneuropathy...